The CCR2 inhibitor Propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic Steatohepatitis

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Mulder, Petra ^a,b   Van Den Hoek, Anita M ^a   Kleemann, Robert ^a,b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARGINASE 1; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CHEMOKINE RECEPTOR CCR2; DEOXYGLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P 15095; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; ARGINASE; CCL2 PROTEIN, MOUSE; CD11 ANTIGEN; ORGANOMETALLIC COMPOUND;

ADIPOSE TISSUE INFLAMMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE TRANSPORT; CELL AGGREGATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; GENE EXPRESSION; GLUCOSE INFUSION; HISTOPATHOLOGY; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; MACROPHAGE; MACROVESICULAR STEATOSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; QUANTITATIVE ANALYSIS; STEATOSIS; TREATMENT DURATION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD11; ARGINASE; CHEMOKINE CCL2; DIET, HIGH-FAT; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGANOMETALLIC COMPOUNDS; RECEPTORS, CCR2;

EID: 85009216397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169740     Document Type: Article

References (37)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nature reviews Gastroenterology & hepatology. 2013; 10(11):686-90.
2. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annual review of pathology. 2010; 5:145-71. doi: 10.1146/annurev-pathol-121808-102132
3. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-Adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006; 131(3):934-45. doi: 10.1053/j.gastro.2006.05.054
4. Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN gastroenterology. 2011; 2011:592404. doi: 10.5402/2011/592404
5. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of clinical investigation. 2003; 112 (12):1796-808. doi: 10.1172/JCI19246
6. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of clinical investigation. 2003; 112(12):1821-30. doi: 10.1172/JCI19451
7. Mulder P, Morrison MC, Wielinga PY, van Duyvenvoorde W, Kooistra T, Kleemann R. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-Alcoholic steatohepatitis in obesity. International journal of obesity. 2015.
8. Ito A, Suganami T, Yamauchi A, Degawa-Yamauchi M, Tanaka M, Kouyama R, et al. Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. The Journal of biological chemistry. 2008; 283(51):35715-23. doi: 10.1074/jbc.M804220200
9. Oh DY, Morinaga H, Talukdar S, Bae EJ, Olefsky JM. Increased macrophage migration into adipose tissue in obese mice. Diabetes. 2012; 61(2):346-54. doi: 10.2337/db11-0860
10. Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 2010; 59(4):916-25. doi: 10.2337/db09-1403
11. Gadd VL, Skoien R, Powell EE, Fagan KJ, Winterford C, Horsfall L, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014; 59(4):1393-405. doi: 10.1002/hep.26937
12. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. The Journal of clinical investigation. 2006; 116(1):115-24 10.1172/JCI24335
13. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. The Journal of clinical investigation. 2006; 116(6):1494-505. doi: 10.1172/JCI26498
14. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. American journal of physiology Gastrointestinal and liver physiology. 2012; 302(11):G1310-21. doi: 10.1152/ajpgi.00365.2011
15. Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol. 2008; 28 (12):2195-201. doi: 10.1161/ATVBAHA.108.168633
16. Tamura Y, Sugimoto M, Murayama T, Minami M, Nishikaze Y, Ariyasu H, et al. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. Journal of atherosclerosis and thrombosis. 2010; 17(3):219-28.
17. Kleemann R, van Erk M, Verschuren L, van den Hoek AM, Koek M, Wielinga PY, et al. Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PloS one. 2010; 5(1): e8817. doi: 10.1371/journal.pone.0008817
18. Hirayama C, Suzuki H, Ito M, Okumura M, Oda T. Propagermanium: A nonspecific immune modulator for chronic hepatitis B. J Gastroenterol. 2003; 38(6):525-32. doi: 10.1007/s00535-003-1098-7
19. Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PloS one. 2014; 9 (12):e115922. doi: 10.1371/journal.pone.0115922
20. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. The Journal of clinical investigation. 2007; 117(1):175-84. doi: 10.1172/JCI29881
21. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-Alcoholic fatty liver disease. Digestive diseases. 2010; 28(1):155-61. doi: 10.1159/000282080
22. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. doi: 10.1053/jhep.2003. 50161
23. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55(5):1389-97. doi: 10.1002/hep.25539
24. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005; 42(5):987-1000. doi: 10.1002/hep.20920
25. Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Current pharmaceutical design. 2013; 19(29):5250-69. doi: 10.2174/13816128113199990344
26. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007; 447(7148):1116-20. doi: 10.1038/nature05894
27. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. The Journal of clinical investigation. 2007; 117(6):1658-69. doi: 10.1172/JCI31561
28. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell metabolism. 2008; 8(4):301-9. doi: 10. 1016/j.cmet.2008.08.015
29. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, et al. Bias in macrophage activation pattern influences non-Alcoholic steatohepatitis (NASH) in mice. Clinical science. 2012; 122(11):545-53. doi: 10.1042/CS20110366
30. Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, et al. CCR2 antagonism in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. Diabetes, obesity & metabolism. 2014; 16(11):1055-64.
31. Yokochi S, Hashimoto H, Ishiwata Y, Shimokawa H, Haino M, Terashima Y, et al. An anti-inflammatory drug, propagermanium, may target GPI-Anchored proteins associated with an MCP-1 receptor, CCR2. J Interferon Cytokine Res. 2001; 21(6):389-98. doi: 10.1089/107999001750277862
32. Yamashita T, Kawashima S, Ozaki M, Namiki M, Inoue N, Hirata K, et al. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler Thromb Vasc Biol. 2002; 22(6):969-74.
33. Shimokawa H, Eto Y, Miyata K, Morishige K, Kandabashi T, Matsushima K, et al. Propagermanium suppresses macrophage-mediated formation of coronary arteriosclerotic lesions in pigs in vivo. J Cardiovasc Pharmacol. 2003; 41(3):372-80.
34. Kitade H, Sawamoto K, Nagashimada M, Inoue H, Yamamoto Y, Sai Y, et al. CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes. 2012; 61(7):1680-90. doi: 10.2337/db11-1506
35. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation. 2007; 115(8):1029-38. doi: 10.1161/CIRCULATIONAHA.106.638379
36. Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. The Journal of clinical investigation. 2010; 120 (11):4129-40. doi: 10.1172/JCI41732
37. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. The Journal of clinical investigation. 2009; 119(7):1858-70. doi: 10.1172/JCI37444